Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Halfmoon Parent, Inc. $20 Billion Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $20 billion…
Zai Lab Limited $150 Million Follow-On Offering of American Depositary Shares
Davis Polk advised Zai Lab Limited in connection with its first follow-on offering of $150 million of American Depositary…
Illumina, Inc. $750 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina,…
Zoetis Inc. $1.5 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300…
Davis Polk Advises ViewRay, Inc. on Its $172.5 Million Follow-On Common Stock Offering
Davis Polk advised ViewRay, Inc. in connection with its $172.5 million SEC-registered follow-on offering of 18,648,649…
NeoGenomics Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
REGENXBIO Inc. $175.5 Million Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000…
BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the…
Davis Polk Advises Pernix on Private Exchange Offers
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing…
Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500…